Compare Enveric Biosciences Inc (ENVB) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Msci Inc — how do they compare? Enveric Biosciences Inc trades at $1.36 (market cap $5.32M), while Msci Inc trades at $630.85 (market cap $45.26B). The key difference: Msci Inc is far larger — about 8507.5× Enveric Biosciences Inc's market cap, and Msci Inc pays a 1.32% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | MSCI | |
|---|---|---|
Market Cap | $5.32M | $45.26B |
Sector | Health | Financials |
52-Week High | $17.40 | $643.83 |
52-Week Low | $1.28 | $511.84 |
Enterprise Value | $408.82K | $51.43B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
MSCI trades at $626.59, up 2.48% today, with strong technical momentum as the stock approaches resistance at $628. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $4.55 versus $4.44, maintaining a three-quarter earnings beat streak. Recent strategic partnerships with UBS and the acquisition of First Street highlight growth initiatives in private markets and climate risk analytics. Valuation metrics show a P/E of 35.51 and P/S of 14.5, reflecting premium pricing for consistent performance.
The outlook remains positive with analyst consensus strongly bullish (73% buy ratings) and a price target of $718.14 offering 15% upside potential. Key risks include high debt levels at $4.51 billion and sensitivity to financial market conditions. The upcoming Q2 2026 earnings report on July 21, 2026, will be critical for validating growth trajectory amid elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
